STOCK TITAN

DiaMedica Therapeutics (DMAC) Stock News, Apr-Aug 2023

DMAC NASDAQ

DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.

Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.40%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
conferences earnings
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
private placement
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.91%
Tags
private placement
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.91%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.77%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
conferences earnings
Rhea-AI Summary

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced the appointment of David Wambeke as Chief Business Officer (CBO) to spearhead business development initiatives. Mr. Wambeke brings over 15 years of life sciences and investment banking experience, having previously been involved in over 100 financing transactions. He will play a crucial role as the company resumes enrollment in its ReMEDy2 trial for acute ischemic stroke (AIS).

In conjunction with his appointment, Mr. Wambeke purchased $750,000 worth of common shares at $1.60 each, above the closing price of $1.57 on April 10, 2023, indicating his vested interest in the company's future. Additionally, he received an inducement stock option for 140,000 common shares with a 10-year term.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
management

FAQ

What is the current stock price of DiaMedica Therapeutics (DMAC)?

DiaMedica Therapeutics (DMAC) last closed at $8.38.

What is the market cap of DiaMedica Therapeutics (DMAC)?

The market cap of DiaMedica Therapeutics (DMAC) is approximately $452.2M.